Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194674 · ClinicalTrials.gov registry record · Phase 1
Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01194674: Clinical Trial Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
NCT01194674 is a Phase 1 study that was terminated before completion, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01194674, a Phase 1 study, was terminated before completion, sponsored by National Institutes of Health Clinical Center (CC).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The objective of this study is to investigate the safety and efficacy of microplasmin as a treatment for uveitic macular edema.
Interventions
- DRUG Microplasmin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Why NCT01194674 stopped before completion
NCT01194674 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Microplasmin is the first listed.
NCT01194674 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01194674 about?
NCT01194674 is a clinical study titled "Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema". The objective of this study is to investigate the safety and efficacy of microplasmin as a treatment for uveitic macular edema.
What is the current status of trial NCT01194674?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2011-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01194674?
The interventions under investigation include: Microplasmin (DRUG).
Who is sponsoring clinical trial NCT01194674?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01194674's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia